Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alnuctamab + mezigdomide
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Alnuctamab + mezigdomide is an investigational combination therapy currently in clinical trials for relapsed and/or refractory multiple myeloma. Alnuctamab is a bispecific monoclonal antibody that targets both B-cell maturation antigen (BCMA) and CD3, redirecting T cells to kill BCMA-expressing myeloma cells. Mezigdomide is a small molecule cereblon E3 ligase modulator (CELMoD) that induces targeted ubiquitination and proteasomal degradation of specific transcription factors (notably IKZF1/Ikaros and IKZF3/Aiolos), leading to immunomodulatory and antineoplastic effects. Preclinical studies demonstrate mezigdomide enhances alnuctamab-mediated T-cell cytotoxicity by increasing immune cell–tumor interactions and T-cell activation. The combination is being assessed for safety, tolerability, and preliminary efficacy in patients previously treated for multiple myeloma, including those with resistance to prior lines of therapy[1][3][5][7][9].
- Other names
- alnuctamab + mezigdomide
02
Targets
CRBN (Cereblon)IKZF3 (Zinc finger protein Aiolos)IKZF1 (Ikaros family zinc finger protein 1)CD3 (T-cell surface glycoprotein CD3)BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on alnuctamab + mezigdomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alnuctamab + mezigdomide.